Template-fixed peptidomimetics with antimicrobial activity
Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa . They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and Solution phase synthetic strategy.
1. A compound represented by formula (I):
wherein
is D Pro- L Pro or L Pro- D Pro and Z is a chain of 12 α-amino acid residues, wherein the positions of the amino acid residues in the chain are counted starting from the N-terminal amino acid, wherein the amino acid residues are, in positions P1 to P12 of the chain:
P1: Ala, Cit, Thr, Thr, Asp, or Glu;
P2: Trp, or Tyr;
P3: Ile, Val, Nle, Chg, or Cha;
P4: Dab, Lys, or Gln;
P5: Lys, Dab, or Orn;
P6: Dab, D Dab, or Lys;
P7: His, Lys, Gln, or Dab;
P8: Tyr, Trp, or Ser;
P9 Dab or Lys;
P10: Dab or Lys;
P11: Ala, Abu, Thr, Gly, Pro, Hse, Ile, Nva, D Ala, D Val, Aib, Nle, Chg, Cha, Gln, Asp, Glu, Cpa, t-BuG, Leu, Val, or Asn; and
P12: Dab, Lys, Gln, or Ser,
or a pharmaceutically acceptable salt or enantiomer thereof.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Gly; and
P12: Dab.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Abu; and
P12: Dab.
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Thr; and
P12: Dab.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Tyr;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Ala;
P2: Trp;
P3: Ile;
P4: Dab
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Lys;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Lys;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Lys.
11. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Gln;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Val;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Dab.
13. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Hse; and
P12: Dab.
14. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Gln;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Gln.
15. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Glu;
P2: Trp;
P3: Ile;
P4: Dab;
P5: Lys;
P6: D Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Gln.
16. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Thr;
P2: Trp;
P3: Ile;
P4: Dab;
PS: Orn;
P6: D Dab;
P7: Dab;
P8: Trp;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Ser.
17. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid residues in positions P1 to P12 of the chain are:
P1: Glu;
P2: Trp;
P3: Ile;
P4: Gln;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Ser;
P9: Dab;
P10: Dab;
P11: Ala; and
P12: Ser.
18. An enantiomer of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which is therapeutically active.
20. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which has selective antimicrobial activity against Pseudomonas aeruginosa.
21. A pharmaceutical composition containing the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically inert carrier.
22. The composition of claim 21 , which is in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.
23. The composition of claim 21 , which is in the form of a tablet, dragee, capsule, solution, liquid, gel, plaster, cream, ointment, syrup, slurry, suspension, spray, nebuliser or suppository.